Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Stock Information for Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.